Partho P. Sengupta, MD, DM

• Associate Professor of Medicine
• Director of Noninvasive Cardiology
• Department of Medicine
• University of California Irvine
• Irvine, California

Evaluation of synergy between carbovir and 3-azido-2 acne studios sale buy 20 gr benzoyl with amex,3-deoxythymidine for inhibition of human immunodeficiency virus type 1 skin care zo discount benzoyl online mastercard. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy skin care jogja purchase benzoyl overnight. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells acne tretinoin cream 005 benzoyl 20 gr. Development and significance of nucleoside drug resistance in infection caused by the human immunodeficiency virus type 1 skin care diet discount benzoyl 20gr otc. Clinical uses of the drug 3695 limited settings: clinical results from 4 African countries. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudineexperienced patients. Infection of human monocytederived macrophages by human immunodeficiency virus mediated by cell-to-cell transmission. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. A trial with 3-azido-2,3dideoxythymidine and human interferon- in cats naturally infected with feline leukaemia virus. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature. Oral mucosa pigmentation: a new side effect of azidothymidine therapy in patients with acquired immunodeficiency syndrome. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Cerebrospinal fluid findings in patients before and during longterm oral zidovudine therapy. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. Restricted transport of 3-azido-3deoxythymidine and dideoxynucleosides through the blood-brain barrier. Inhibition of visna virus replication by 2,3 -dideoxynucleosides and acyclic nucleoside phosphonate analogs. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antiviral effects of 3-azido-3deoxythymidine, 2,3-dideoxycytidine, and 2,3-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro. Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings. Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. Kinetics and inhibition of reverse transcriptase from human and simian immunodeficiency viruses. Response of humanimmunodeficiency-virus-associated neurological disease to 3azido-3-deoxythymidine. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. Although international guidelines no longer contain didanosine-containing regimens in preferred first- or second-line antiretroviral therapy, there is no guidance for management of patients who remain on didanosine. In 2012 at least 20 countries spent a total of $1 to $2 million on purchasing didanosine (Dziuban et al. The concentration can be expressed as in micromolars or micrograms per milliliter (1 µg/ml is approximately equivalent to 5 µM). A compound that is closely related to didanosine, 2,3dideox-yadenosine (ddA) was first synthesized in 1964 (Robins and Robins, 1964). At relatively high concentrations (10­100 µM) didanosine reportedly inhibits reverse transcription in resting T-lymphocytes (Watson and Wilburn, 1992). Didanosine has little or no in vitro activity against Pneumocystis jiroveci (Walzer et al. The L74V reverse transcriptase mutation by itself conferred only limited resistance to didanosine and was associated with limited cross-resistance to zalcitabine, abacavir, and lamivudine but not to zidovudine (St. Emergence of the L74V mutation is independent of zidovudine-related mutations (Masquelier et al. This L74V didanosine signature mutation can also be selected in patients failing abacavir, and as a consequence didanosine therapy is not a preferred option in those patients (Miller et al. Another mutation at this codon L74I may represent a different mutation pathway (Wirden et al. Didanosine and dideoxyadenosine, in contrast to zidovudine, do not inhibit replication of murine leukemia virus (Dahlberg et al. Compared with zidovudine, didanosine results in only modest inhibition of feline leukemia virus (Tavares et al. Simian immunodeficiency virus is also inhibited by didanosine (Connolly and Hammer, 1992). Moloney murine sarcoma virus is inhibited in vitro and in vivo by didanosine (Balzarini et al. Visna virus replication is inhibited by didanosine in vitro, although this drug is 10- to 30-fold less effective than zalcitabine in inhibiting virus-induced syncytium formation (Thormar et al. Didanosine and zidovudine can also inhibit human foamy virus replication in vitro (Santillana-hayat et al. Reverse transcriptase mutation, K65R, can be selected in vitro by passage in the presence of increasing concentrations of zalcitabine as well as in vivo from patients treated with didanosine, abacavir, or tenofovir. This mutation has been associated with in vitro didanosine resistance with crossresistance to zalcitabine, abacavir, lamivudine, emtricitabine, and tenofovir (Gu et al. The M184V mutation has been found by some investigators to confer resistance to didanosine in vitro with crossresistance to zalcitabine or lamivudine (Boucher et al. In addition, this mutation has been detected in isolates from patients receiving long-term didanosine therapy (Gu et al. Other investigators have found that this same mutation at codon 184 is associated with up to 1000-fold resistance to lamivudine with only a 4- to 8-fold decrease in susceptibility to didanosine (Gao et al. Combinations of multiple mutations or insertions in the reverse transcriptase gene have also been associated with multinucleoside reverse transcriptase inhibitor resistance (Johnson et al. The 69 insertion complex consisting in a substitution at codon 69 and an insertion of two or more amino acids is associated with resistance to all nucleoside reverse transcriptase inhibitors when present with one or more thymidine analog-associated mutations and can be selected by didanosine therapy (De Antoni et al. The Q151M multiresistance complex affects all currently approved nucleoside reverse transcriptase inhibitors. Mutations at codons 62, 75, 77, and 116 are usually associated with the Q151M mutation. These mutations have been detected in isolates from patients receiving combination therapy with zidovudine, zalcitabine, stavudine, or didanosine (Lacey and Larder, 1994; Shirasaka et al. In addition, combinations of thymidine-associated mutations selected by the thymidine analogs zidovudine and stavudine are associated with cross-resistance to all nucleoside reverse transcriptase inhibitors. In vivo studies have shown that the presence of three or more of the thymidine-associated mutations M41L, D67N, L210W T215Y/F, and K219Q/E are associated with resistance to didanosine (Marcelin et al. However, the K70R mutation is not associated with a decreased virologic response to didanosine (Molina et al. A scoring system for didanosine resistance mutations has been validated (Assoumou et al. The following mutations were given scores as follows: M41L (score of 14), T69D (24), D123S (40), T139M (54), I180V (53), M184V (­12), V189I (55), Q207K (37), L210W (25), and T215Y (8). These scores were validated from clinical data showing that viral loads decreased by 1. Phenotypic resistance tests can also be used to assess didanosine resistance in vivo. Unlike with protease inhibitors, the establishment of clinically relevant cutoffs for these assays is difficult for nucleoside analogs because very small increases in phenotypic susceptibility are associated with major differences in antiviral activity in vivo. Other authors have reported that the evolution of resistance pathways may significantly differ in non-B subtypes under selective pressure: in another small study of individuals who failed a zidovudine and didanosine dual regimen, T215Y was followed by D67N, K70R in individuals infected with subtype C (Novitsky et al. It is clear that both didanosine and ddA can diffuse into the cell without active transport; this is similar to zidovudine but differs from zalcitabine (McGowan et al. The dideoxyribose sugar moiety can also be cleaved from didanosine by the enzyme purine nucleoside phosphorylase, forming hypoxanthine and subsequently uric acid (Shelton et al. Zidovudine, didanosine, and lamivudine in combination have greater antiviral activity in vitro than double-drug combinations or monotherapy (St. Hydroxyurea (50 µM) has been reported to increase the antiretroviral activity of didanosine in vitro (Palmer et al. Unlike zidovudine and zalcitabine, the effects of didanosine are not reversed by the addition of the naturally occurring 2-deoxynucleoside, even when added in 20-fold excess (Mitsuya et al. This dosing interval is based on the finding that the intracellular half-life of the triphosphate active compound is prolonged when compared with the didanosine plasma half-life (Ahluwalia et al. Even with the new entericcoated formulation, however, didanosine should be taken on an empty stomach at least 30 minutes before a meal. Indeed, previous studies with the tablet formulation have shown that higher doses are more likely to be associated with adverse reactions without further clinical benefit (Kahn et al. In phase I studies the maximum tolerated dose in patients treated for 28­44 weeks was 12 mg/kg daily (Cooley et al. Hydrolysis of didanosine at the C­N glycosidic bond results in the formation of hypoxanthine and deoxyribose with loss of antiretroviral activity (Mitsuya et al. In hydrochloric acid at pH 2 the half-life of the initial formulation of didanosine was only a few minutes (Marquez et al. The current formulation of didanosine as enteric-coated capsules protects didanosine from gastric acid. The capsule, which contains enteric-coated didanosine beadlets, is dissolved in the stomach, but the enteric coating results in the liberation of didanosine in the duodenum, where the pH becomes neutral or alkaline, and the absorption continues throughout the small intestine. Different formulations of didanosine are available: Delayed-release capsules, containing enteric-coated beadlets, are available for oral administration in strengths of 125, 200, 250, and 400 mg of didanosine. Enteric coating is used to protect didanosine from degradation by stomach acid pH. Pediatric unbuffered powder for oral solution: supplied in 120- and 240-ml bottles containing 2 and 4 g, respectively. Newborn infants and children Pediatric dosing guidelines are based on average surface area (see Table 226. For children over 8 months of age, a daily dose of 240 mg/m2 didanosine powder for oral solution given as once- or twice-daily dosing is safe and effective. For children between 2 weeks and 8 months of age the recommended daily dose is 200 mg/m2. Dosing recommendations in infants younger than 2 weeks of age cannot be made because the pharmacokinetics of didanosine in these children is too variable to determine an appropriate dose (Balis et al. In animal studies in rats and rabbits using doses with 12 times human exposure there was no harm to the fetus. During lactation these high doses resulted in mild abnormalities, including reduced weigh gain. Fatal lactic acidosis resulted from use of didanosine and stavudine together in pregnant women. Patient population Adults (body weight) > 60 kg < 60 kg Children (body surface area, m2) < 2 weeks of age 2 weeks to 8 months of age > 8 months of age a Pediatric powder for oral solution. Dose 400 mg once daily or 200 mg twice daily 250 mg once daily or 125 mg twice daily Dose tablets (powder)a No dosing recommendation can be made because didanosine pharmacokinetics is too variable 100 mg/m2 twice daily. Pharmacokinetics and pharmacodynamics 3703 There have been no adequate studies of didanosine in pregnant women so the drug should not be used unless potential benefit is considered to outweigh potential harm. In two women in their second trimester of pregnancy, a single oral dose of 375 mg resulted in no alteration in pharmacokinetic parameters. However, concentrations in fetal sera were < 20% of maternal serum concentrations (Pons et al. In another study, the ratio between the concentration of didanosine in maternal plasma and that in cord blood plasma was only 0. Although no dosage recommendations exist at present for pregnant women, it is likely that didanosine does not cross the placenta as well as the other nucleoside analogs. Also, elderly patients are more likely to have decreased renal function; therefore, care should be taken in dose selection in these patients. Absorption of didanosine is greater in the jejunum than in other parts of the intestine (Mirchandani and Chien, 1995); colorectal absorption has also been reported (Bram et al. The mean oral bioavailability varies with different preparations, and in early studies ranged from 17% to 43% (Hartman et al.

Drug resistance in cytomegalovirus: current knowledge and implications for patient management acne xia buy discount benzoyl on line. Diagnosis and management of human B virus (herpesvirus simiae) infections in Michigan acne gluten cheap benzoyl generic. Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation skin care physicians purchase benzoyl amex, even during rejection treatment acne 50 year old male order 20gr benzoyl with mastercard. Successful treatment with ganciclovir of presumed Epstein­Barr meningo-encephalitis following bone marrow transplant acne vs rosacea purchase 20 gr benzoyl amex. A comparison of ganciclovir and aciclovir to prevent cytomegalovirus after lung transplantation. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. Management and prevention of cytomegalovirus infection after renal transplantation. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Zidovudine antagonizes the antiviral effects of ganciclovir against cytomegalovirus infection in cultured cells and in guinea pigs. Long acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cystosine. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. Efficacy of ganciclovir in combination with zidovudine against cytomegalovirus in vitro and in vivo. Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Activity of 9-(1,3-dihydroxy2-propoxymethyl)guanine compared with that of aciclovir against human, monkey and rodent cytomegaloviruses. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Early treatment with aciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. Ganciclovir therapy of symptomatic cytomegalovirus infection in renal transplant recipients. Pharmacokinetics of 2,3-dideoxyinosine in patients with severe human immunodeficiency infection. A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbit. Progression rates of cytomegalovirus retinopathy in ganciclovir-treated and untreated patients. Cholestasis and disseminated cytomegalovirus disease in patients with the acquired immunodeficiency syndrome. Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: A phase I study. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir. Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Prophylactic versus preemptive oral valganciclvoir for the management of cytomegalovirus infection in adult renal transplant recipients. Polyradiculopathy due to cytomegalovirus: report of two cases in which improvement occurred after prolonged therapy and review of the literature. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. Use of valganciclovir in patients with elevated antibody titers against human herpesvirus-6 and Epstein­Barr virus who were experiencing central nervous system dysfunction including long-standing fatigue. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Treatment of cytomegalovirus enterocolitis with ganciclovir in an infant with acquired immunodeficiency syndrome. Metabolic activation of 9([2hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human lymphoblastoid cell lines infected with Epstein­Barr virus. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein­Barr virus. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients, Infectious Disease Working Party of the European Group for Bone Marrow Transplantation. Disseminated cytomegalovirus infection in an immunocompetent adult successfully treated with ganciclovir. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Ganciclovir for the treatment of cytomegalovirus pneumonia in an immunocompetent host. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Effect of 9-(1,3-dihydroxy-2propoxymethyl)guanine on human cytomegalovirus replication in vitro. Cytomegalovirus infection of the larynx in the acquired immunodeficiency syndrome. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Cytomegalovirus retinopathy and the acquired immune deficiency syndrome: results of treatment with ganciclovir. Human cytomegalovirus induces a cellular deoxyguanosine kinase, also interacting with aciclovir. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. Combined therapy with recombinant granulocyte colony stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. Should heart­lung transplant donors and recipients be matched according to cytomegalovirus serologic status Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized controlled trial. Stability of ganciclovir sodium in 5% dextrose injection and in 09% sodium chloride injection over 35 days. Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection. Lack of antiviral activity of ketoconazole alone or in combination with the acyclic nucleoside ganciclovir against a herpes virus type 2 infection in mice. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Ganciclovir treatment of cytomegalovirus ventriculitis in a patient infected with human immunodeficiency virus. Three dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient. Treatment of ganciclovir resistant cytomegalovirus with foscarnet: A report of two cases occurring after bone marrow transplantation. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Treatment of cytomegalovirus pneumonia with 9-[2-hydroxyl-1-(hydroxymethyl) ethoxymethyl] guanine and high dose corticosteroids. Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection. Antiviral therapy with ganciclovir for cytomegalovirus retinitis and bilateral exudative retinal detachments in an immunocompromised child. Oral valganciclovir versus intravenous ganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients. Cytomegalovirus retinitis in pediatric acquired immunodeficiency syndrome report of two cases. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. Intraocular 9-([2-hydroxy1-(hydroxymethyl) ethoxy] methyl) guanine levels after intravitreal and subconjunctival administration. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Activity of 9-[2-hydroxy-1(hydroxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Comparative antiherpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, aciclovir, and two 2-fluoropyrimidine nucleosides. Anti herpesvirus activity of the acyclic nucleoside 9-(1,3-hihydroxy-2-propoxymethyl) guanine. A new nucleoside analog, 9-[[2-hydroxymethyl) ethoxyl]methylguanine, highly active in vitro against herpes simplex virus types 1 and 2. Cytomegalovirus infection in heart­lung transplant recipients: risk factors, clinical associations and response to treatment.

Benzoyl 20gr low cost. Nivea Cream Soft Soap Review ll Fairness soap kya ye Sabun face ke liye Good hai ya Bad janiye.

Drugs with similar toxicity profiles that may lead to additive toxicity acne 5 days past ovulation discount benzoyl american express, with minimal or no pharmacokinetic interactions acne at 30 buy benzoyl 20 gr, when co-administered include amphotericin B acne x out buy benzoyl toronto, dapsone skin care 8 year old order 20 gr benzoyl with amex, doxorubicin acne keloidalis nuchae surgery discount benzoyl online, flucytosine, pentamidine, trimethoprim­sulfamethoxazole, mycophenolate mofetil, vinblastine, and vincristine and probably zidovudine (Genentech, 2014). The prevalence of bone marrow suppression varies widely, depending on the route of administration, the dose, underlying illness, and the definition of neutropenia. The development of neutropenia has been reported to be independent of the duration of treatment, plasma drug levels, or baseline neutrophil count (Reed et al. Peritoneal dialysis, hemodialysis, hydration, exchange transfusion, or treatment with colony-stimulating factors may be useful and prevent the development of adverse events (Roche, data on file). However, the manufacturer recommends that gonadal toxicity be assumed until further clinical data are available (Roche, data on file). However, higher doses administered to mice and dogs were associated with the development of testicular atrophy, with an increased incidence of abnormal morphology of spermatozoa (at a dose of 20­1000 mg/kg daily) and of tumors of the clitoris and stomach (1000 mg/kg daily). In dogs administered up to 6 mg/kg daily for 1 year, toxicities included low leukocyte counts (at a dose of 6 mg/kg daily), and at doses of 0. A pooled sample from two clinical studies reported 27% neutropenia, 26% anemia, and 6% thrombocytopenia out of 370 patients (Genentech, 2015). In the era before effective combination antiretroviral therapy became widely available. This study also used independent assessments of fundus photography to determine time to progression. After 8 weeks of maintenance therapy (1 injection per week) the relapse rate was 53%. Involvement of the other eye occurred in 11% and systemic disease in 16% of patients (CochereauMassin et al. Combination foscarnet and ganciclovir therapy was reported to be of clinical benefit for this condition in two cases (Karmochkine et al. The largest of these was the prospective double-blind placebo-controlled trial conducted by Wohl et al. Two subsequent single-center retrospective studies have evaluated the impact of preemptive treatment in similar populations, but they have had mixed results. Patients receiving preemptive treatment experienced substantial drug toxicities, most commonly neutropenia and anemia. Detailed international consensus guidelines for each approach have been developed by a panel of clinical experts (Tomblyn et al. Detailed international consensus guidelines for each approach have been developed by a panel of clinical experts (Kotton et al. Generally, universal prophylaxis or preemptive therapy are considered effective options, though universal prophylaxis tends to be preferred in high-risk transplant recipients. There was no evidence of higher late-onset infections, but a 4-year followup is under way. However, symptomatic infection was more common in the prophylaxis group, with 5 patients developing any symptoms compared to 1 patient in the preemptive group. Neutropenia occurred in 4% of patients, with no difference in bacterial infections noted between arms. Therapy costs were 7% greater with the prophylaxis arm compared to the preemptive arm. No differences in efficacy or tolerability were noted among different organ transplant recipients. Despite these mixed results, it has become standard of practice to administer some type of prophylactic regimen based on the high risk of infection in these patients and positive outcomes in other solid organ transplant patients (Kalil et al. More recent studies have evaluated the optimal duration of prophylaxis in this high-risk group. The longer duration of therapy was also associated with lower rates of viremia (64% vs. The extended duration of therapy was generally well tolerated, although 56­78% of patients reported some degree of nausea, emesis, diarrhea, or anorexia, and five patients developed an intravenous catheter-related infection. There are little data from prospective randomized trials limited to liver transplantation. However, none of these subset differences was statistically significant, nor was there an organ type difference at 12 months. Clinical response, as measured by resolution of fever, usually occurs within 2­9 days (mean 5. The investigators enrolled 96 neonates with gestational age 32 weeks and postnatal age 30 days. Those receiving 6 months of treatment were more likely to have improved or have normal hearing at 12 months compared with those treated for 6 weeks (73% vs, 57%, respectively; p = 0. They also had modestly improved scores on neurodevelopmental screening tests (Kimberlin et al. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Outcome of cytomegalovirus retinitis in immunocompromised patients without human immunodeficiency virus treated with intravitreal ganciclovir injection. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomised cytomegalovirus retinitis trial. Mortality in patients with acquired immune deficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. The principle is to make tumor cells susceptible to chemotherapy by transfecting them with a gene that activates a cytocidal drug. This strategy is being investigated for the treatment of pleural mesothelioma, glioblastoma multiforme, and prostatic cancer. Posttreatment antibodies to the adenovirus were noted in a majority of patients, but two patients with long-term followup were noted to have had a clinical response (Sterman et al. Although a clinical response was noted, approximately half the patients experienced serious adverse events, possibly related to the treatment modality (Prados et al. In a phase I study, the adenovirus vector was directly injected into the tumor of patients with prostatic cancer that locally recurred after hormonal therapy. Oral valganciclovir is noninferiour to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir as preemptive therapy for cytomegalovirus reactivation in pediatric hematopoietic stem cell transplant patients. Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients. A modified procedure for intravitreal injections of ganciclovir in the treatment of cytomegalovirus retinitis. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl) guanine in human diploid fibroblasts infected with human cytomegalovirus. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. Absence of cytomegalovirusresistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous haemodialysis. Modified high-performance liquid chromatographic method for the determination of ganciclovir in plasma from patients with severe renal impairment. Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein­Barr virus. Ganciclovir treatment of life or sight threatening cytomegalovirus infection; experience in 314 immunocompromised patients. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients. Effect of prophylactic ganciclovir on renal function and cyclosporine levels after heart transplantation. Ganciclovir treatment of cytomegalovirus infection in heart-lung and double lung transplant recipients. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Controlled trial of prophylaxis versus therapeutic use of ganciclovir after liver transplantation in adults. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to aciclovir and ganciclovir. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. Virological, clinical and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells. Acute lumbosacral polyradiculopathy in acquired immunodeficiency syndrome: Experience in 23 patients. Effect of 9-(1,3-dihydroxy2-propoxymethyl)guanine and recombinant human beta-interferon alone and in combination on simian varicella virus infection in monkeys. Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis and herpesvirus infections. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Toxicity of 3-azido-3-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Successful treatment with ganciclovir of disseminated cytomegalovirus infection after liver transplantation. Treatment of cytomegalovirus pneumonitis with ganciclovir in renal transplantation. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose 3530 Ganciclovir and Valganciclovir adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirusinfected cells. Ganciclovir therapy for cytomegalovirus disease associated with renal transplants. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation. Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line. Unexpectedly high interand intrapatient variability of ganciclovir levels in children. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxy1-(hydroxymethyl) ethoxymethyl] guanine. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Results of a placebo controlled double blind trial. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Potent inhibition of Epstein­Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification. It was marketed by Gilead Sciences under the trade name of Vistide, and in June 2010 the patent expired. In March 2013, InnoPharma (which was acquired by Pfizer in July 2014) launched the generic equivalent of Vistide). In contrast to the phosphate group, a phosphonate group cannot be cleaved off by cellular hydrolases (esterases).

Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open label fixed sequence study in healthy subjects acne nyc purchase 20 gr benzoyl fast delivery. Fosamprenavir plus ritonavir increase plasma ketoconazole and ritonavir exposure skin care steps buy benzoyl with amex, while amprenavir exposure remains unchanged acne after stopping birth control benzoyl 20 gr with mastercard. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug acne location buy benzoyl with a visa. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors acne jensen boots cheap benzoyl 20 gr line. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. Immature viral Gag and Gag­Pol polyproteins are processed by cleavage to form structural and enzyme components, before assembly into nascent, infectious virions. Darunavir is a synthetic nonpeptidyl small molecule analog of amprenavir that inhibits the dimerization and catalytic activity of the protease enzyme (Hayashi et al. The chemical structure of darunavir is similar to that of amprenavir; however, the presence of additional hydrogen bonds between darunavir and the protease enzyme result in a strength of binding two orders of magnitude higher: the equilibrium dissociation constant (Kd) for darunavir is 4. In Australia, this fixeddose combination was registered under the trade name Prezcobix in September 2015. Emerging resistance and cross-resistance Darunavir has a very high genetic barrier to resistance (Lefebvre and Schiffer, 2008). The development of resistance to darunavir in vitro appears to occur more slowly and is more difficult to generate than is resistance to other protease inhibitors such as nelfinavir, amprenavir, and lopinavir (Lefebvre et al. Furthermore, the protease inhibitor mutations generated in these serial passage experiments, R41T and K70E, were not associated with reduced susceptibility to protease inhibitors, either in clinical isolates or when introduced into laboratory strains by site-directed mutagenesis (De Meyer et al. Seven mutations developed in patients who experienced virological failure, and these were I15V, V32I, L33F, M46I, I47V, L89V, and I54L. Of these, V32I and I54L were the most common, occurring in more than 20% of the analyzed virological failures. In this study, the rate of virological failure was up to 10% (31/298 patients) in the darunavir arm. Of those who developed virological failure, researchers identified I13V, V32I, M36L, I50V, I54L, V771, and L89M as being treatment emergent mutations (Blanche et al. At week 96, only 75% of those on darunavir monotherapy remained virologically suppressed compared to 85% of those on triple therapy. Despite this, no treatment-emergent primary darunavir mutations were noted (Girard et al. Mechanism of action 4127 darunavir resistance associated mutations increased from 77. In clinical studies of treatment-experienced patients, minimal cross-resistance was observed between darunavir and tipranavir. Patients who experienced virological rebound on darunavir treatment retained tipranavir susceptibility on testing (Arasteh et al. Darunavir acts predominantly within the substrate envelope, displaying a high affinity for its target, with a binding constant of 4. The terminal bis-tetrahydrofuran group is of major importance to the potency of the agent, due to formation of hydrogen bonds between the two oxygen atoms of this moiety and the amide groups of the Asp-29 and Asp-30 residues on the protease backbone (Surleraux et al. Conformational analysis studies have demonstrated that darunavir exhibits both rigid and flexible docking within the active site of a range of both wild-type and mutant proteases, forming highly stable complexes (Nivesanond et al. Sources: Data compiled from de Meyer (2008) and Stanford University 2014 database (Rhee, 2003). Halving of tablets is not recommended as dose equivalence with divided tablets has not been established (Janssen, 2015b). Pediatric dosing for weight > 15 kg: treatmentnaive and -experienced patients without darunavir-associated mutations. Weight 15­< 30 kg 30­< 40 kg 40 kg Darunavir dose 600 mg once daily 675 mg once daily 800 mg once daily Ritonavir dose 100 mg once daily 100 mg once daily 100 mg once daily 4a. Pregnant and lactating mothers Although there are no controlled trials evaluating the dose of darunavir during pregnancy, a number of small studies have provided information. Once-daily dosing of darunavir boosted with ritonavir (800/100 mg) in 16 pregnant women during their second and third trimesters of pregnancy and postpartum has revealed an approximately 35% decrease in total darunavir exposure during pregnancy, compared to postpartum. The changes are not considered to be sufficient for the authors to recommend dose modification (Crauwels et al. Darunavir plasma trough concentrations were measured in 20 pregnant women receiving darunavir as part of their antiretroviral regimen. The mean darunavir plasma trough concentration deceased from 3790 ng/ml in the first trimester to 1288 ng/ml (p = 0. The fixed-dose combination of darunavir­cobicistat (Prezcobix) is not currently recommended in treatmentexperienced adults. In the presence of one or more major darunavir resistance mutations (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V), darunavir should be administered at a dose of 600 mg twice daily, co-administered with ritonavir. Similarly, in treatment-experienced adults with prior protease inhibitor-exposure but no available genotype testing, twice-daily dosing is recommended. In the setting of a high viral load (100,000 copies/ml) in treatment-experienced adults, twice-daily dosing is recommended (Janssen, 2015b). Newborn infants and children Darunavir should not be used in children aged < 3 years of age, due to adverse effects, including seizures and death, as seen in juvenile rats in preclinical studies. In Australia, darunavir is currently registered for use in children aged 6 to under 18 years. Pediatric dosing for weight > 15 kg: treatmentexperienced patients with at least one darunavir-associated mutation. Weight 15­< 30 kg 30­< 40 kg 40 kg Darunavir dose 375 mg twice daily 450 mg twice daily 600 mg twice daily Ritonavir dose 50 mg twice daily 60 mg twice daily 100 mg twice daily 5. While these authors suggested that an increased, twice-daily dose may be needed there is no recommendation for an altered dose in pregnancy by the manufacturers. The unbound (active) fraction of darunavir did not differ during pregnancy; 12% during pregnancy and 10% postpartum (Colbers et al. The manufacturer recommends caution in using this agent in patients aged > 65 years (Janssen, 2015a). Bioavailability Absorption of darunavir is rapid after oral administration, with the Cmax being achieved 2. Bioavailability after a single 600 mg dose of darunavir alone is 37%, whereas boosting with ritonavir yields a bioavailability of 82% (Janssen, 2015a). Bioequivalence has been demonstrated between the 800 mg darunavir tablet and two 400 mg tablets, in both fed and fasted conditions (Kakuda et al. Comparable bioavailability has also been demonstrated for the fixed-dose combination darunavir­cobicistat (800/150 mg) once daily and darunavir­ ritonavir (800/100 mg) once daily (Kakuda et al. When healthy volunteers were administered darunavir at 600 mg twice daily with ritonavir, Cmax in the nonfasted state ranged from 5. Oncedaily ritonavir-boosted darunavir (at 800/100 mg) yielded a Cmax in healthy controls of 7. When cobicistat (150 mg) was co-administered with 800 mg of darunavir, Cmax was 7. Ritonavir inhibits P-glycoproteinmediated efflux, thereby leading to increased absorption of darunavir (Fujimoto et al. Cmax is increased by up to 30% when darunavir is ingested with food, although the type of food appears to make no difference (Sekar et al. This effect has also been demonstrated when cobicistat is used as a pharmacological enhancer (Kakuda et al. The estimated drug exposure after once- or twice-daily boosted darunavir has been reported as median population pharmacokinetic estimates in both adults and children (Janssen, 2015a). However, due to its limited renal clearance, a significant decrease in total drug excretion would not be expected. Moreover, both darunavir and ritonavir are highly protein bound in plasma and, therefore, unlikely to be significantly cleared by dialysis. Population pharmacokinetic data demonstrate that darunavir is not significantly affected by the presence of mild to moderate renal impairment (creatinine clearance [CrCl]: 30­60 ml/minute) and no dose adjustment is required (Janssen, 2015a). Patients co-infected with hepatitis B and/or C were included in trials of both treatment-naive and -experienced patients. Limited data are available regarding the use of darunavir in patients with severe hepatic impairment and its use is not recommended in this setting. In a subgroup of patients with co-existent viral hepatitis, darunavir was associated with lower rates of transaminase derangement than in the lopinavir-containing comparator arm (Orkin et al. In a treatment-experienced cohort, there were similar rates of grade 2­4 transaminase elevations in darunavir-treated patients versus the lopinavir comparator arm (Madruga et al. In two studies in which maternal and cord plasma trough darunavir levels were available in pregnant women receiving darunavir boosted with ritonavir, 800/100 mg once daily, the median cord/maternal blood ratio in the two studies was similar: 0. All three primary metabolites are at least 10-fold less potent than darunavir itself. Three minor metabolites M27, M28, and M6 have also been elucidated (Rittweger and Arasteh, 2007). Studies using radiolabeled drug have demonstrated that excretion is primarily in feces (79. Hepatotoxicity During clinical development involving a large cohort of > 3000 participants exposed to darunavir, hepatotoxicity developed in 0. Patients with preexisting liver disease, including chronic viral hepatitis, were at higher risk (Janssen, 2015a). In treatment-naive participants, the incidence of grade 3 or 4 elevations in transaminase levels was low, being 1. Postmarketing cases of severe liver injury, including fulminant hepatitis leading to death, have been reported, although a causal relationship to darunavir was not established (Janssen, 2015a). Clinically important pharmacokinetic and pharmacodynamic features Findings from a prospective observational study where 150 patients with virologic suppression were switched from triple therapy to receive ritonavir-boosted darunavir monotherapy (800 mg darunavir/100 mg ritonavir) once daily have demonstrated that the darunavir Cmin correlated with virological control, with higher Cmin present during undetectable viremia. Dose reduction may be necessary Use with caution Avoid co-administration Use with caution Sildenafil dose should be < 25 mg in 48 hours; vardenafil at a single dose < 2. Rash and severe cutaneous reactions Although darunavir-associated rash is relatively common, occurring in up to 11% of patients in one observational study, the drug can usually be continued with the use of antihistamines or oral steroids (Nishijima et al. Darunavir boosted with ritonavir (800/100 mg) administered once daily is associated with a higher rate of skin rash than other protease inhibitor­containing regimens, as reported in a study of Taiwanese patients (Lin et al. The rash tends to develop early, within the first month of treatment, and is usually mild to moderate, allowing continuation of treatment with darunavir. Because darunavir contains a sulfonamide moiety, it should be used with caution in patients with sulfonamide allergies. During clinical development studies, severe cutaneous and soft tissue reactions occurred in 0. There is also no consistent reduction in plasma markers of inflammation, immune activation, and coagulation at 96 weeks in patients randomized to receive these regimens, despite virologic suppression (Kelesidis et al. And the incidence of metabolic syndrome was approximately 22% in patient groups on these regimens (Ofotokun et al. These rates of dyslipidemia compared favorably with the lopinavir-containing comparator arm. The use of boosted darunavir has been evaluated in both treatmentnaive and treatment-experienced adults, adolescents, and children as outlined in this section. Boosted darunavir was compared to boosted lopinavir, used in combination with a backbone of tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg once daily. Darunavir was dosed at 800 mg once daily, in combination with 100 mg ritonavir, whereas lopinavir was administered at a total daily dose of 800 mg, in combination with 200 mg ritonavir and was dosed either once or twice daily. The primary end point was noninferiority in terms of virological response at 48 weeks, defined as the percentage of patients achieving a viral load < 50 copies/ml. A noninferiority analysis was conducted in the per protocol population, with a predefined 12% noninferiority margin; after this criterion was met, subsequent superiority testing was performed in the intent-to-treat population. At 48 weeks, boosted darunavir was noninferior to lopinavir in terms of the proportion of patients achieving virological suppression, with 83. Subsequent followup at 96 and 192 weeks demonstrated that darunavir was significantly more effective at maintaining 7. Clinical use of the drug 4135 virological suppression at these time points, with darunavir being superior regardless of whether lopinavir was administered once or twice daily (79% vs. When stratified by viral load, significantly more patients with high viral loads (> 100,000 copies/ ml) at baseline in the darunavir arm achieved virological suppression at all time points studied. The primary reason for discontinuation of darunavir was "loss to followup," which accounted for 6. Rates of self-reported adherence were not significantly different between the two arms of the study. Rates of toxicity-related drug discontinuation were not statistically significant between the darunavir and raltegravir arm, at 4. Dolutegravir met prespecified criteria for both noninferiority and superiority at both the 48- and 96-week time points. At 48 weeks, 90% of patients in the dolutegravir arm versus 83% in the darunavir arm had achieved virological suppression. By 96 weeks, 80% in the dolutegravir arm and 68% in the darunavir arm were virologically suppressed. Rates of virological failure, defined as two consecutive viral loads > 200 copies/ml after 24 weeks, were low in both arms: 1% in the dolutegravir arm versus 2% with darunavir by 96 weeks. None of the patients with virological failure showed evidence of treatment-emergent resistance to any of the drug classes used. There was a trend toward higher rates of treatment failure in the group, with a high baseline viral load (> 100,000 copies/ml); however, this did not reach statistical significance.

References

• Gabella G: Structure of smooth muscles. In Szekeres L, Gy J, editors: Handbook of experimental pharmacology, vol 111, Berlin Heidelberg, 1994, Springer Verlag, pp 3n34. Gearhart JP, Lee RL, Partin AW, et al: A quantitative histological evaluation of the dilated ureter of childhood. II. Ectopia, posterior urethral valves and prune belly syndrome, J Urol 153:172, 1995.
• Falci DR, da Rosa FB, Pasqualotto AC. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. Mycoses. 2015;58(2):104-112.
• Troost, B. (2002). Botulinum toxin-type A (Botox, Allergan, Irvine, CA) therapy for intractable headaches [Abstract]. Presented at the American Headache Society Meeting, Seattle, WA, June 21nJune 23.
• Edwards WD. Classification and terminology of cardiovascular anomalies. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adults, 7th edition. Lippincott Williams and Wilkins; 2001, pp. 118-39.
• Messerli FH. Cerebroprotection by hypertension in ischemic stroke: the crumbling of a hypothesis. Circulation. 2007;115(23):2907-2908.
• Abali G, Tokgozoglu L, Ozcebe OI, et al: Which Doppler parameters are load independent? A study in normal volunteers after blood donation, J Am Soc Echocardiogr 18:1260-1265, 2005.
• Amanatkar HR, Chibnall JT, Seo BW, et al: Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebocontrolled trials, Ann Clin Psychiatry 26:19n32, 2014.